Antagonists of AT1 receptors are promising candidates in the therapy of various neuropathological conditions, such as stroke, neurodegenerative disorder or traumatic brain injury or mood disorders, and DM-related cognitive impairment [32]. The gene discussed is AGTR1; the disease is injury.